A citation-based method for searching scientific literature

Atul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, Alexa P Kollmeier, Elizabeth C Hsia, Ramanand A Subramanian, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang, Christopher T Ritchlin. Lancet 2020
Times Cited: 101







List of co-cited articles
1010 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Philip J Mease, Proton Rahman, Alice B Gottlieb, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang,[...]. Lancet 2020
98
76


Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn,[...]. Lancet 2013
521
31

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G McGonagle, Daniel Aletaha, Andra Balanescu,[...]. Ann Rheum Dis 2020
269
29

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.
Laura C Coates, Arthur Kavanaugh, Philip J Mease, Enrique R Soriano, Maria Laura Acosta-Felquer, April W Armstrong, Wilson Bautista-Molano, Wolf-Henning Boehncke, Willemina Campbell, Alberto Cauli,[...]. Arthritis Rheumatol 2016
525
28

Psoriatic Arthritis.
Christopher T Ritchlin, Robert A Colbert, Dafna D Gladman. N Engl J Med 2017
582
27

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, Masato Okada, Raquel S Cuchacovich, Catherine L Shuler, Chen-Yen Lin, Daniel K Braun, Chin H Lee, Dafna D Gladman. Ann Rheum Dis 2017
306
26

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Iain B McInnes, Philip J Mease, Bruce Kirkham, Arthur Kavanaugh, Christopher T Ritchlin, Proton Rahman, Désirée van der Heijde, Robert Landewé, Philip G Conaghan, Alice B Gottlieb,[...]. Lancet 2015
526
25

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Philip J Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert,[...]. Ann Rheum Dis 2020
108
23

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Philip J Mease, Iain B McInnes, Bruce Kirkham, Arthur Kavanaugh, Proton Rahman, Désirée van der Heijde, Robert Landewé, Peter Nash, Luminita Pricop, Jiacheng Yuan,[...]. N Engl J Med 2015
486
23

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David H Adams, Lisa Kerr, Chin Lee, Catherine L Shuler,[...]. Lancet 2017
219
23

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Philip Mease, Stephen Hall, Oliver FitzGerald, Désirée van der Heijde, Joseph F Merola, Francisco Avila-Zapata, Dorota Cieślak, Daniela Graham, Cunshan Wang, Sujatha Menon,[...]. N Engl J Med 2017
261
22

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
Atul Deodhar, Alice B Gottlieb, Wolf-Henning Boehncke, Bin Dong, Yuhua Wang, Yanli Zhuang, William Barchuk, Xie L Xu, Elizabeth C Hsia. Lancet 2018
103
21


Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
Iain B McInnes, Frank Behrens, Philip J Mease, Arthur Kavanaugh, Christopher Ritchlin, Peter Nash, Jordi Gratacós Masmitja, Philippe Goupille, Tatiana Korotaeva, Alice B Gottlieb,[...]. Lancet 2020
79
25

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Dafna Gladman, William Rigby, Valderilio F Azevedo, Frank Behrens, Ricardo Blanco, Andrzej Kaszuba, Elizabeth Kudlacz, Cunshan Wang, Sujatha Menon, Thijs Hendrikx,[...]. N Engl J Med 2017
249
19

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
P J Mease, R Fleischmann, A A Deodhar, J Wollenhaupt, M Khraishi, D Kielar, F Woltering, C Stach, B Hoepken, T Arledge,[...]. Ann Rheum Dis 2014
305
19


Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
Dominique Baeten, Mikkel Østergaard, James Cheng-Chung Wei, Joachim Sieper, Pentti Järvinen, Lai-Shan Tam, Carlo Salvarani, Tae-Hwan Kim, Alan Solinger, Yakov Datsenko,[...]. Ann Rheum Dis 2018
177
17

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Philip J Mease, Dafna D Gladman, Christopher T Ritchlin, Eric M Ruderman, Serge D Steinfeld, Ernest H S Choy, John T Sharp, Peter A Ory, Renee J Perdok, Mark A Weinberg. Arthritis Rheum 2005
679
17

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
278
17

Classification criteria for psoriatic arthritis: development of new criteria from a large international study.
William Taylor, Dafna Gladman, Philip Helliwell, Antonio Marchesoni, Philip Mease, Herman Mielants. Arthritis Rheum 2006
16

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt. Lancet 2019
128
16

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells.
Jonathan P Sherlock, Barbara Joyce-Shaikh, Scott P Turner, Cheng-Chi Chao, Manjiri Sathe, Jeff Grein, Daniel M Gorman, Edward P Bowman, Terrill K McClanahan, Jennifer H Yearley,[...]. Nat Med 2012
694
16

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Christopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, Georg Schett, Jose U Scher, Richard B Warren, Alice B Gottlieb, Deepak Assudani, Kathy Bedford-Rice, Jason Coarse,[...]. Lancet 2020
66
24

Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
Iain B McInnes, Proton Rahman, Alice B Gottlieb, Elizabeth C Hsia, Alexa P Kollmeier, Soumya D Chakravarty, Xie L Xu, Ramanand A Subramanian, Prasheen Agarwal, Shihong Sheng,[...]. Arthritis Rheumatol 2021
16
93

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
Arthur Kavanaugh, Philip J Mease, Juan J Gomez-Reino, Adewale O Adebajo, Jürgen Wollenhaupt, Dafna D Gladman, Eric Lespessailles, Stephen Hall, Marla Hochfeld, ChiaChi Hu,[...]. Ann Rheum Dis 2014
287
14

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
Arthur Kavanaugh, Iain McInnes, Philip Mease, Gerald G Krueger, Dafna Gladman, Juan Gomez-Reino, Kim Papp, Julie Zrubek, Surekha Mudivarthy, Michael Mack,[...]. Arthritis Rheum 2009
444
14

Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
Elizabeth G Araujo, Matthias Englbrecht, Sabrina Hoepken, Stephanie Finzel, Eleni Kampylafka, Arnd Kleyer, Sarah Bayat, Verena Schoenau, Axel Hueber, Juergen Rech,[...]. Semin Arthritis Rheum 2019
62
22

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.
Philip J Mease, Alice B Gottlieb, Désirée van der Heijde, Oliver FitzGerald, Alyssa Johnsen, Marleen Nys, Subhashis Banerjee, Dafna D Gladman. Ann Rheum Dis 2017
117
13

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Philip Mease, Désirée van der Heijde, Robert Landewé, Shephard Mpofu, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Karin Meiser,[...]. Ann Rheum Dis 2018
142
13

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.
Atul Deodhar, Lianne S Gensler, Joachim Sieper, Michael Clark, Cesar Calderon, Yuhua Wang, Yiying Zhou, Jocelyn H Leu, Kim Campbell, Kristen Sweet,[...]. Arthritis Rheumatol 2019
150
13

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
Philip J Mease, Alan J Kivitz, Francis X Burch, Evan L Siegel, Stanley B Cohen, Peter Ory, David Salonen, Joel Rubenstein, John T Sharp, Wayne Tsuji. Arthritis Rheum 2004
684
13

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
C Antoni, G G Krueger, K de Vlam, C Birbara, A Beutler, C Guzzo, B Zhou, L T Dooley, A Kavanaugh. Ann Rheum Dis 2005
520
13

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Dominique Baeten, Joachim Sieper, Jürgen Braun, Xenofon Baraliakos, Maxime Dougados, Paul Emery, Atul Deodhar, Brian Porter, Ruvie Martin, Mats Andersson,[...]. N Engl J Med 2015
576
13

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny,[...]. Arthritis Rheumatol 2019
179
13

Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
Philip J Mease, Mark C Genovese, Maria W Greenwald, Christopher T Ritchlin, André D Beaulieu, Atul Deodhar, Richard Newmark, JingYuan Feng, Ngozi Erondu, Ajay Nirula. N Engl J Med 2014
269
12

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial.
Philip J Mease, Dafna D Gladman, David H Collier, Christopher T Ritchlin, Philip S Helliwell, Lyrica Liu, Gregory Kricorian, James B Chung. Arthritis Rheumatol 2019
88
13

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny,[...]. Arthritis Care Res (Hoboken) 2019
125
12

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Kristian Reich, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, Nicole Cichanowitz, Qing Li,[...]. Lancet 2017
288
12

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.
B Oppmann, R Lesley, B Blom, J C Timans, Y Xu, B Hunte, F Vega, N Yu, J Wang, K Singh,[...]. Immunity 2000
11

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
L Gossec, J S Smolen, S Ramiro, M de Wit, M Cutolo, M Dougados, P Emery, R Landewé, S Oliver, D Aletaha,[...]. Ann Rheum Dis 2016
581
11

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Philip Mease, Laura C Coates, Philip S Helliwell, Mykola Stanislavchuk, Anna Rychlewska-Hanczewska, Anna Dudek, Walid Abi-Saab, Chantal Tasset, Luc Meuleners, Pille Harrison,[...]. Lancet 2018
98
11

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Christian E Antoni, Arthur Kavanaugh, Bruce Kirkham, Zuhre Tutuncu, Gerd R Burmester, Udo Schneider, Daniel E Furst, Jerry Molitor, Edward Keystone, Dafna Gladman,[...]. Arthritis Rheum 2005
483
11

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
Maurizio Cutolo, Gary E Myerson, Roy M Fleischmann, Frédéric Lioté, Federico Díaz-González, Filip Van den Bosch, Helena Marzo-Ortega, Eugen Feist, Kamal Shah, ChiaChi Hu,[...]. J Rheumatol 2016
116
11

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).
Peter Nash, Philip J Mease, Iain B McInnes, Proton Rahman, Christopher T Ritchlin, Ricardo Blanco, Eva Dokoupilova, Mats Andersson, Radhika Kajekar, Shephard Mpofu,[...]. Arthritis Res Ther 2018
71
15

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Christopher J Edwards, Francisco J Blanco, Jeffrey Crowley, Charles A Birbara, Janusz Jaworski, Jacob Aelion, Randall M Stevens, Adele Vessey, Xiaojiang Zhan, Paul Bird. Ann Rheum Dis 2016
154
11

The pathogenesis of psoriatic arthritis.
Douglas J Veale, Ursula Fearon. Lancet 2018
178
11

Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints.
Marie-Astrid Boutet, Alessandra Nerviani, Gabriele Gallo Afflitto, Costantino Pitzalis. Int J Mol Sci 2018
88
12

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.
Craig A Murphy, Claire L Langrish, Yi Chen, Wendy Blumenschein, Terrill McClanahan, Robert A Kastelein, Jonathon D Sedgwick, Daniel J Cua. J Exp Med 2003
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.